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Clinical Implications207 Early onset infections, including pulmonary infections,
mucocutaneous candidiasis, and skin abscesses, strongly
suggest the diagnosis of signal transducer and activator of
transcription 3-hyper-IgE syndrome. Eczema associated
with high IgE levels is not discriminatory between
patients with signal transducer and activator of
transcription 3-hyper-IgE syndrome and those with
undetermined hyper-IgE syndrome.TO THE EDITOR:
The hyper-IgE syndromes are primary immunodeﬁciencies
characterized by elevated serum IgE level, eosinophilia, eczema,
and recurrent skin and sinopulmonary infections. Heterozygous
dominant-negative mutations of signal transducer and activator
of transcription 3 (STAT3) constitute the most common cause of
the autosomal-dominant form of hyper-IgE syndrome (AD-
HIES).1-4 AD-HIES represents a multisystem disease where the
immune disorder is associated with connective tissue and skeletal
abnormalities, but other genes, such as DOCK8, TYK2, PGM3,
CARD11, and ZNF341, can lead to HIES-like phenotypes. To
identify the distinctive features required for an early diagnosis of
AD-HIES,5 we analyzed the clinical and immunologic features of
61 patients who were referred because of high IgE levels (>2000
IU/mL) and underwent STAT3 genetic sequencing.
We identiﬁed 14 distinct heterozygous mutations in 28 of 61
patients analyzed (46%) (see Figure E1 in this article’s Online
Repository at www.jaci-inpractice.org). Patients carrying the
D371-G380del, N567D, M660A, and V463del mutations have
been previously described.6-8 The 33 patients with STAT3 wild-
type mutations were classiﬁed as suffering from undetermined
hyper-IgE syndrome (U-HIES).2Themean age at onset was 0.97 years in patients with AD-HIES
(range, birth-6.08 years), whereas it was higher (5.07 years) in
subjects with U-HIES (range, birth-24 years) (Figure 1, A; see
Table E1 in this article’s Online Repository at www.jaci-
inpractice.org). The median age at diagnosis was 14.76 years in
the AD-HIES cohort (range, 0.4-46.3 years) and 9.18 years in the
U-HIES cohort (range, 1-55 years) (Figure 1, A). The detection of
increased IgE levels as ﬁrst manifestation was predictive of negative
genetic analysis (0% vs 30%; P < .001) (Figure 1, B).
Most patients presented with eczema as ﬁrst clinical symptom
(43% in patients with AD-HIES vs 58% in patients with
U-HIES; P ¼ .474). Atopic dermatitiselike eczema is one of the
main features of AD-HIES but even if common in STAT3-
mutated patients (88.5%), it also occurred in individuals with
U-HIES (60.6%) (P ¼ .016). Eczema was classiﬁed as persistent,
severe, or scattered, but none of these features correlated with an
increased risk of STAT3 mutation. In contrast, a strictly speciﬁc
feature of STAT3 deﬁciency was the appearance of newborn rash
(57.7% of patients with AD-HIES vs 6.1% of patients with
U-HIES; P < .001).
Early onset of infections was observed mostly in patients with
STAT3 mutations (57% vs 6%; P < .001). Overall, infectious
diseases were more common in STAT3-deﬁcient patients, but
some infectious manifestations were more strictly associated with
STAT3 mutation. In particular, mucocutaneous candidiasis
(70.1% in AD-HIES vs 3% inU-HIES) and skin abscesses (77.8%
vs 6.1%) were strongly associated with AD-HIES (P < .001,
respectively), whereas pyodermitis (32% vs 18.2%), molluscum
contagiosum (8.3% vs 0%), and warts (4.2% vs 0%) were not
speciﬁc (P ¼ .182, 0.173, and 0.421, respectively).
In AD-HIES, patients presenting with respiratory infections,
upper respiratory tract infections (URTIs), and pneumonia were
common (77.8% in AD-HIES vs 60% in U-HIES). Neverthe-
less, URTIs and pneumonia were also frequently observed in
patients with U-HIES (27.3% and 24.2%, respectively). Among
URTIs, sinusitis was more strictly associated with AD-HIES
than was otitis (P ¼ .003 and P ¼ .078, respectively) (Figure 2).
Viral infections were identiﬁed mostly in AD-HIES (26.1% vs
3%; P ¼ .015). STAT3-mutated patients presented with recur-
rent herpesvirus infection reactivation (n ¼ 3), skin infections
caused by Molluscum contagiosum and Papillomavirus (n ¼ 3),
and cytomegalovirus viremia (n ¼ 1). One patient with U-HIES
had a systemic varicella-zoster viral infection. Two episodes of
septic arthritis were reported in the U-HIES cohort.
A single fatal infection occurred in a patient with AD-HIES
because of disseminated fungal infection at the age of 46 years.
Severe infections, deﬁned as sepsis, meningitis, osteomyelitis, and
disseminated fungal and viral infections, occurred more frequently
in patients with AD-HIES (23.1%), but were observed sporadi-
cally in patients with U-HIES (9.1%) (P ¼ .132).
Patients with AD-HIES who presented an infection as ﬁrst
clinical manifestation at onset showed a slightly increased risk to
develop a severe infectious complication during lifetime (P¼ .034).
Conversely, we observed more allergic manifestations in patients
withU-HIES (60.6% vs 25%; P¼ .008), particularly the frequency
FIGURE 1. A,Mean age at onset and diagnosis in the STAT3-mutated cohort, compared with the U-HIES cohort. The mean age at onset
was 0.97 years in the STAT3-mutated cohort, compared with 5.07 years in the U-HIES cohort. The mean age at diagnosis was 14.76
years in the STAT3-mutated cohort and 9.18 years in the STAT3-negative cohort. B, First clinical manifestation at disease onset in the
STAT3-mutated cohort, compared with the U-HIES cohort. Most patients presented with eczema as first clinical symptom. Individuals
who had an infection as first manifestation had an increased probability to be STAT3-mutation carriers. In contrast, the detection of
increased IgE levels as first manifestation was predictive of a negative genetic analysis.
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by nuts occurred in a patient with AD-HIES at the age of 30 years.6
Skeletal and connective tissue abnormalities were observed
only in the cohort of patients with STAT3 mutations and
included typical facial appearance (84%), retained primary teeth
(65.4%), scoliosis (42.3%), high-arched palate (40%), and joint
hyperextensibility (32%). Craniosynostostosis was observed in a
single patient with AD-HIES. Notably, not all the typical facial
abnormalities appeared early in life.
Lung complications, such as bronchiectasis (53.4%), pneuma-
toceles (39.4%), ﬁbrosis (3.6%), and emphysema (3.6%), were
detected by chest computed tomography (CT) scan in half
the patients with AD-HIES and only in a single individual with
U-HIES (P < .001) (Figure 2). Five patients with AD-HIES with
severe lung disease (35.7%) underwent lung resection.However, early diagnosis of AD-HIES was associated with a
better pulmonary outcome, as the median age at diagnosis was
19.6  10.4 years in the group of patients with AD-HIES with
lung disease, as compared with 7.3  10.5 years in the group of
patients with AD-HIES without lung damage. In patients with
STAT3 mutations, lung disease was associated with recurrent
pneumonia (P < .001).
Malignancies occurred only in STAT3-mutated patients: 2 of
them developed non-Hodgkin lymphoma, whereas another one
had a thyroid carcinoma. However, the limited number of cases
was not sufﬁcient to prove an increased risk of malignancies in
patients with AD-HIES (P ¼ .080). Fractures appearing after
minor trauma were observed only in patients with AD-HIES (P¼
.001), whereas no cardiovascular, neurological, and autoimmune
manifestations were recognized in both groups of patients.
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FIGURE 2. Clinical manifestations and disease complications of patients with AD-HIES as compared with patients with U-HIES. Pneu-
monia with lung disease, skin abscesses, mucocutaneous candidiasis, and newborn rash were highly specific of AD-HIES (P < .001),
whereas allergic manifestations and asthma were more common in patients with U-HIES (P ¼ .008 and P ¼ .003, respectively).
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found with a similar distribution in both cohort of patients. The
detection of elevated speciﬁc IgE levels did not correlate with an
increased frequency of allergic manifestations or asthma in both
cohorts (P ¼ .051 and P ¼ .315, respectively).
Staphylococcus aureus and Pseudomonas aeruginosa isolates were
detected only in patients with AD-HIES, whereas S aureus
colonization of skin and nasal mucosa and respiratory airways
colonization by Haemophilus inﬂuenzae and Streptococcus pneu-
moniae were seen in both groups.
Overall, our study reveals that early appearance of rash,
mucocutaneous candidiasis, skin abscesses, or pneumonia is
highly speciﬁc of AD-HIES, whereas allergic manifestations were
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METHODS
Patients
Sixty-one individuals with IgE levels of greater than
2000 IU/mL have been retrospectively analyzed. Twenty-eight
patients with diagnosis of AD-HIES entered the Italian Pri-
mary Immunodeﬁciency Network (IPINet) registry. In each of
the IPINet center, patients with AD-HIES are managed ac-
cording to the HIES IPINet protocol. Thirty-three individuals
from different Italian hospitals were referred to our department
with the clinical suspicion of HIES because of their clinical
presentation and the detection of high serum IgE levels
(>2000 IU/mL), but their molecular sequencing of STAT3
was negative. In these patients, secondary causes of elevated
serum IgE levels (ie, parasitic and other infectious diseases,
malignancies, inﬂammatory disorders, other primary immu-
nodeﬁciencies) had been previously ruled out. Clinical and
laboratory data were retrospectively collected by the referring
physicians throughout a speciﬁc questionnaire. Patients, or
their parents in the case of minors, gave written informed
consent. Approval for this study was obtained by the institu-
tional review board of Spedali Civili of Brescia (NP 2834).
Sequencing
Patients with elevated IgE levels were analyzed for STAT3
mutations at the Institute of Molecular Medicine “Angelo
Nocivelli” of Brescia, or were previously reported.E1,E2 Genomic
DNA was isolated from 200 mL of blood samples by the DNeasy
kit (Qiagen, Hilden, Germany) puriﬁcation method. By PCR,
with speciﬁc primers, exons 1 to 24 of STAT3 and their ﬂanking
introns were ampliﬁed. Then, they were sequenced using the Big
Dye Terminator kit (Applied Biosystems, Waltham, Mass) and
the ABI Prism 310 Analyzer (Applied Biosystems). Finally, the
sequences were analyzed by using the BioEdit sequence software(Carlsbad, Calif). Computational analysis with PoliPhen-2 was
used to predict the possible impact of STAT3 mutations on the
structure and the function of the protein. Among the patients
with STAT3 wild-type mutations, only the ones with a suggestive
clinical presentation were further analyzed for DOCK8, TYK2,
or PGM3. Individuals found to harbor mutations in other HIES-
causing genes (ie, DOCK8) were excluded from the analysis.
Clinical and immunologic investigations
Data collection included investigation of the past medical
history focusing on the familiarity for immunologic diseases,
infections (site and etiology, if available), autoimmune manifes-
tations, allergies, and malignancies. In details, allergic disease was
deﬁned by the report of allergic rhinitis, asthma, food allergy, or
anaphylaxis. The physical examination explored signs of infec-
tion or infective complications (ie, signs of sinusitis, pulmonary
disease, and cutaneous manifestations), characteristic face, skel-
etal, and dental abnormalities, and vascular and neurological
anomalies. Analysis of speciﬁc IgE panels (ImmunoCAP) was
used to measure the levels of speciﬁc allergen-reactive IgE.
Microbiological analysis included serological screening for viruses
(ie, human simplex virus, varicella-zoster virus, hepatitis C virus,
hepatitis B virus, cytomegalovirus, and EBV) and microbial
culture. Radiologic examinations (skeletal or chest X-ray and
thoracic computed tomography scan) and spirometry were per-
formed according to the clinical history.
Statistical analysis
The analysis was processed using the software STATA14
(StataCorp, College Station, Texas). Qualitative variables were
analyzed using Fisher exact test, whereas continuous variables
were compared by Student t test or Wilcoxon signed-rank test.
The relative P value was considered signiﬁcant when found less
than .05.
TABLE E1. Clinical features and laboratory data of 61 individuals with elevated IgE levels referred for genetic analysis of STAT3
Patients’ features Immunologic analyses
Pt Group Sex
Age at
onset (y)
Age at
diagnosis (y) First symptom WBC (cells/mL) L (cells/mL) E (%) E (cells/mL) IgE (UI/mL) IgG (mg/dL) IgA (mg/dL) IgM (mg/dL)
1 STAT3 AD-HIES F 4 35 Infection 4,320 1,092 3.2 138 1,251 1,060 135 62
2 STAT3 AD-HIES F Newborn 1 Eczema 6,280 3,564 4.9 307 5,000 1,047 102 99
3 STAT3 AD-HIES F 0.2 36 Infection 5,210 NA 7.7 401 5,000 1,100 135 91
4 STAT3 AD-HIES M Newborn 0.4 Eczema 31,010 5,750 60 18,606 961 201 52 76
5 STAT3 AD-HIES M Newborn 2 Eczema 21,150 4,575 11.9 2,516 5,000 819 44 86
6 STAT3 AD-HIES M 1.4 12 Infection 6,510 3,211 5 325 5,299 1,077 235 119
7 STAT3 AD-HIES M 0.2 11 Infection 10,600 NA 11 1,166 43,320 1,603 8 210
8 STAT3 AD-HIES M 2 27 Infection 7,900 NA 14 1,106 3,211 1,176 228 192
9 STAT3 AD-HIES F 0.2 11 Infection 12,940 2,588 14 1,811 54,805 3,299 339 140
10 STAT3 AD-HIES M 0.1 3 Eczema 10,700 2,511 17 181 5,380 1,361 102 123
11 STAT3 AD-HIES M 0.1 35 Eczema 8,200 NA 3.7 303 5,040 NA NA NA
12 STAT3 AD-HIES M 2 16 Infection 5,480 1,554 15 822 8,117 1,083 224 186
13 STAT3 AD-HIES F 4 12 Infection 12,800 2,560 1 128 13,000 3,135 156 854
14 STAT3 AD-HIES F Newborn 5 Eczema 12,040 2,640 5 602 22,610 1,560 79 249
15 STAT3 AD-HIES M Newborn 24 Infection 6,700 1,860 6 402 12,743 1,450 159 68
16 STAT3 AD-HIES M 0.2 0.6 Eczema NA NA NA NA NA NA NA NA
17 STAT3 AD-HIES F 0.7 3 Eczema 5,730 2,750 3 170 5,000 1,059 198 67
18 STAT3 AD-HIES F 0.1 11 Infection 6,700 2,650 NA NA 5,000 1,160 306 140
19 STAT3 AD-HIES M 1 46 Eczema NA NA NA NA NA NA NA NA
20 STAT3 AD-HIES M 0.1 6 Infection 17,900 3,225 13 2,300 4,118 1,560 42 76
21 STAT3 AD-HIES M Newborn 0.7 Eczema 22,510 4,970 16.6 4,430 1,034 1,034 64 72
22 STAT3 AD-HIES F 6 17 Infection 9,650 2,490 2.4 230 1,370 1,400 166 124
23 STAT3 AD-HIES F 0.2 10 Eczema 4,900 2,580 4 196 2,000 1,400 68 52
24 STAT3 AD-HIES M 0.2 5 Infection 8,280 4,730 9 720 5,000 9,970 801 995
25 STAT3 AD-HIES M 1 30 Eczema 3,100 1,176 5 155 12,464 839 106 163
26 STAT3 AD-HIES F NA NA Infection NA NA NA NA NA NA NA NA
27 STAT3 AD-HIES M NA NA Infection NA NA NA NA 13,600 NA NA NA
28 STAT3 AD-HIES F NA NA Infection NA 3,570 NA 200 3,130 NA NA NA
29 U-HIES M 15 17 High IgE 5,710 2,166 0.5 NA 5,000 3,333 308 159
30 U-HIES M NA 5 Eczema 10,610 4,000 22.1 NA 5,000 1,415 169 89
31 U-HIES M 12 13 High IgE 8,710 2,900 26 2,200 915 1,242 138 87
32 U-HIES F 5 5 High IgE 9,160 3,900 NA 1,050 3,046 923 95 46
33 U-HIES M 3 7 Infection 5,660 2,470 4.2 237 4,456 1,660 187 62
34 U-HIES F 5 6 Eczema 6,740 2,010 NA 900 3,997 670 129 52
35 U-HIES F 6 10 High IgE 4,950 2,240 2 240 659 1,030 165 85
36 U-HIES M 4 4 High IgE 6,720 2,400 2.6 174 3,898 NA NA NA
37 U-HIES M 1 4 Eczema 10,010 3,670 NA 680 3,856 993 92 62
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TABLE E1. (Continued)
Patients’ features Immunologic analyses
Pt Group Sex
Age at
onset (y)
Age at
diagnosis (y) First symptom WBC (cells/mL) L (cells/mL) E (%) E (cells/mL) IgE (UI/mL) IgG (mg/dL) IgA (mg/dL) IgM (mg/dL)
38 U-HIES M 3 3 Eczema 8,590 4,300 3 NA 680 1,070 90 148
39 U-HIES M 3 5 Eczema 10,840 6,400 5.1 552 5,000 NA NA NA
40 U-HIES M 0.9 1 Eczema 16,790 12,390 NA 690 4,338 829 57 80
41 U-HIES F NA 10 Eczema 6,140 2,200 2.4 150 5,000 1,242 109 73
42 U-HIES M 3 3 Eczema 8,470 5,150 13 1,030 5,000 NA NA NA
43 U-HIES M 1 4 Eczema 6,310 2,700 13.4 840 3,600 840 86 64
44 U-HIES F 24 32 Eczema 12,440 2,400 NA 1,200 5,000 619 160 43
45 U-HIES M Newborn 2 Eczema 9,870 4,600 25 2,000 5,000 660 32 88
46 U-HIES M 1 3 High IgE 13,570 7,000 9.1 1,230 2,229 1,190 79 55
47 U-HIES F 7 7 Diarrhea 8,400 3,800 7.6 630 2,245 1,320 152 112
48 U-HIES M 2 2 High IgE 8,870 3,900 18.8 1,670 4,434 942 54 118
49 U-HIES M 1 4 Eczema 8,690 3,000 NA 1,300 4,689 1,103 149 121
50 U-HIES M 0.8 2 Infection 13,470 4,300 4.9 600 5,000 1,080 111 118
51 U-HIES M 0.6 1 Eczema 11,720 6,000 NA NA 5,805 705 133 64
52 U-HIES M 0.4 5 Eczema 11,990 4,790 NA 790 4,465 1,073 187 117
53 U-HIES M 1 5 Eczema 9,230 4,330 NA NA 5,000 1,170 126 57
54 U-HIES F 0.7 4 High IgE 11,230 5,020 13.9 1,560 92 1,380 128 97
55 U-HIES F 10 10 High IgE 8,470 3,770 20.4 1,727 776 1,021 129 188
56 U-HIES F 8 8 High IgE 7,300 3,200 11.6 846 2,716 NA NA NA
57 U-HIES M Newborn 10 Eczema 7,460 3,680 9.1 678 3,130 724 103 29
58 U-HIES M 0.2 25 Eczema 10,030 2,100 10.8 1,083 5,000 1,340 380 1,143
59 U-HIES F 23 55 Aphthosis 8,150 3,000 6.5 529 1,533 950 207 92
60 U-HIES F Newborn 9 Eczema 8,210 3,000 16.4 1,346 5,000 993 157 83
61 U-HIES F 8 8 Eczema 4,970 2,880 NA 430 4,149 892 133 92
E, Eosinophils; F, female; L, lymphocytes; M, male; NA, not available; Pt, patient; WBC, white blood cell.
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FIGURE E1. Schematic representation of the human STAT3 pro-
tein structure. We identified 14 distinct heterozygous mutations
localizing to the DNA-binding domain (7), the eSH2 domain (4),
the transactivation domain (2), and the linker domain (1),
respectively.
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